Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/EMA401> ?p ?o }
Showing triples 1 to 75 of
75
with 100 triples per page.
- EMA401 abstract "EMA401 is a new drug under development for the treatment of peripheral neuropathic pain. It was recently established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pains caused by lesions and other diseases affecting the somatosensory system in addition to postherpetic neuralgia. EMA401 has been implicated in alleviating pains associated with a host of neural abnormalities, ranging from excessive nerve sprouting due to damaged nerve caused by shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (AT2R) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. It is the S-enantiomer form of the racemate drug EMA400. Analgesic treatments currently available for pain disorders are unsuited for severe chronic neuropathic pains. EMA401 is more effective and has virtually no central nervous system side effects in comparison to current drugs for pain relief, such as Neurotin and Lyrica. Pain pathways of the other functional systems have major molecular and mechanistic differences compared to pain pathways of the peripheral nervous system. EMA401 target proteins, angiotensin II type 2 receptors, are extremely important for nociception within the peripheral nervous system and less so for nociception within other functional systems. EMA401 is the first drug on the market that targets angiotensin II type 2 receptors (AT2R) with high affinity but has a low affinity for angiotensin II type 1 receptors. Angiotensin II receptor antagonists that have existed in the pharmaceutical market have had higher affinities for angiotensin II type 1 receptors (AT1R) over type 2 receptors. AT1R are not involved with nociception. AT1R antagonists have been mostly used for the treatment of hypertension.".
- EMA401 bioavailability "33.0".
- EMA401 thumbnail EMA401.svg?width=300.
- EMA401 wikiPageExternalLink chronic-constriction-injury.
- EMA401 wikiPageExternalLink EMA401-DEVELOPMENT.html.
- EMA401 wikiPageExternalLink TrialReview.aspx?id=347597.
- EMA401 wikiPageExternalLink paintypes.
- EMA401 wikiPageID "42433109".
- EMA401 wikiPageLength "33889".
- EMA401 wikiPageOutDegree "23".
- EMA401 wikiPageRevisionID "706837549".
- EMA401 wikiPageWikiLink Analgesic.
- EMA401 wikiPageWikiLink Angiotensin.
- EMA401 wikiPageWikiLink Category:Drugs_acting_on_the_nervous_system.
- EMA401 wikiPageWikiLink Category:Receptor_antagonists.
- EMA401 wikiPageWikiLink Central_nervous_system.
- EMA401 wikiPageWikiLink Competitive_inhibition.
- EMA401 wikiPageWikiLink Neuropathic_pain.
- EMA401 wikiPageWikiLink Nociception.
- EMA401 wikiPageWikiLink Pain.
- EMA401 wikiPageWikiLink Peripheral_nervous_system.
- EMA401 wikiPageWikiLink Postherpetic_neuralgia.
- EMA401 wikiPageWikiLink Racemic_mixture.
- EMA401 wikiPageWikiLink Sensitization.
- EMA401 wikiPageWikiLink Somatosensory_system.
- EMA401 wikiPageWikiLink TRPV1.
- EMA401 wikiPageWikiLink Warner–Lambert.
- EMA401 wikiPageWikiLink File:EMA401_Mechanism_of_Action.jpg.
- EMA401 wikiPageWikiLink File:Synthesis_of_EMA401.jpg.
- EMA401 bioavailability "33.0".
- EMA401 boilingPoint "745.3".
- EMA401 c "32".
- EMA401 casNumber "1316755".
- EMA401 chebi "150942".
- EMA401 chembl "34124".
- EMA401 chemspiderid "8068121".
- EMA401 density "1.256".
- EMA401 eliminationHalfLife "-43200.0".
- EMA401 h "29".
- EMA401 image "EMA401 3D.jpg".
- EMA401 iupacName "-2".
- EMA401 legalStatus "Phase II Clinical Trials".
- EMA401 molecularWeight "507.58".
- EMA401 n "1".
- EMA401 o "5".
- EMA401 proteinBound "Angiotensin II Subtype 2 Receptor".
- EMA401 pubchem "9937291".
- EMA401 routesOfAdministration "Oral".
- EMA401 smiles "COC1=COCC5=CC=CC=C5".
- EMA401 solubility "14".
- EMA401 specificRotation "+".
- EMA401 stdinchi "1".
- EMA401 stdinchikey "GHBCIXGRCZIPNQ-UHFFFAOYSA-N".
- EMA401 wikiPageUsesTemplate Template:Infobox_drug.
- EMA401 wikiPageUsesTemplate Template:Orphan.
- EMA401 wikiPageUsesTemplate Template:Peptidergics.
- EMA401 wikiPageUsesTemplate Template:Reflist.
- EMA401 wikiPageUsesTemplate Template:Sub.
- EMA401 wikiPageUsesTemplate Template:Sup.
- EMA401 subject Category:Drugs_acting_on_the_nervous_system.
- EMA401 subject Category:Receptor_antagonists.
- EMA401 hypernym Drug.
- EMA401 type ChemicalSubstance.
- EMA401 type Drug.
- EMA401 type ChemicalObject.
- EMA401 type Thing.
- EMA401 type Q8386.
- EMA401 comment "EMA401 is a new drug under development for the treatment of peripheral neuropathic pain. It was recently established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pains caused by lesions and other diseases affecting the somatosensory system in addition to postherpetic neuralgia.".
- EMA401 label "EMA401".
- EMA401 sameAs Q18388936.
- EMA401 sameAs m.010qtbz_.
- EMA401 sameAs Q18388936.
- EMA401 wasDerivedFrom EMA401?oldid=706837549.
- EMA401 depiction EMA401.svg.
- EMA401 isPrimaryTopicOf EMA401.